gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · NVCRHealthcareSurgical Instruments

NovoCure Limited Ordinary Shares (NVCR)

$14.61+8.79%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$14.61▲ 21.75% in range
Nov 4, 2025Low $10.03 · High $19.99Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

NovoCure Limited closed at $14.61 on Nov 4, up 8.79%, 26.9% below its 52-week closing high. Volume of 1.6M shares was 0.84× its 20-day average (close to normal).

Split-adjusted performance: -2.4% over one month, -11.4% over six months, +19.5% over one year.

In the quarter ended Sep 30, 2026, revenue was $193.40M, up 15.7% from a year earlier, with a net margin of -5.4%.

Short interest was 12.8M shares at the Oct 15 settlement, up 14.9% from the prior report (12.2% of float, 7.7 days to cover).

Market cap$1.71B116.9M shares
Revenue · quarter$193.4M+15.7% YoY
Diluted EPS$-0.09—
P/E · TTM—P/S 2.4×
Net margin-5.4%Gross 77.0%
Dividend yieldNone
52-week range10.03 – 19.99−26.9% from high
Volume1.6M0.84× 20-day avg
Volatility · 60d49.9%Annualised
Short % of float12.2%7.7 days to cover
Net cash$267.1MCash $463.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +3.1%1M −2.4%3M −6.9%6M −11.4%YTD +13.0%1Y +19.5%3Y +11.9%5Y −86.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum45
Revenue growth67
Net margin54
Value (low P/E)—
Size75

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short12.8M+14.9% vs prior
Days to cover7.7Settled Oct 15
% of float12.2%
Short vol. 10d49.7%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NVCRNovoCure Limited$14.61+8.79%−11.4%+15.7%−5.4%—$1.71B
KMTSKestra Medical Technologies$30.50+5.14%+47.3%+59.9%−142.3%—$1.82BCompare
INSPInspire Medical Systems$66.61+7.61%+45.8%−7.9%−11.8%19.1$1.93BCompare
LMATLeMaitre Vascular$87.92+9.08%−20.2%+9.6%24.2%30.6$2.01BCompare
TNDMTandem Diabetes Care$19.05+7.93%+5.7%+5.8%−8.3%—$1.33BCompare
AORTArtivion$26.45+11.56%−23.8%+11.3%−10.7%—$1.29BCompare
ATECAlphatec Holdings$8.28+10.84%+18.5%+12.6%−2.5%—$1.27BCompare
PRCTPROCEPT BioRobotics$21.66+7.39%−12.7%+19.3%−28.4%—$1.24BCompare
IARTIntegra LifeSciences$14.82+8.73%+5.9%+2.3%3.6%88.6$1.15BCompare

News about NovoCure Limited

All news →
NovoCure: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 3d ago▲ PositiveNovocure Reports Patient Data Exposure in Cybersecurity IncidentZacks Investment Research · Sep 7, 2026NeutralFDA Approves First-of-Its-Kind Device to Treat Pancreatic CancerGlobeNewswire Inc. · Feb 12, 2026▲ PositiveStock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Jobs Report—Micron, Novocure, Fastly In Focus (UPDATED)Benzinga · Feb 12, 2026▲ Positive

Quick answers

What does NovoCure Limited do?
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers.
What is NVCR's market cap?
$1.71B, based on the Nov 4 close of $14.61.
Does NovoCure Limited pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NVCR is sold short?
12.8M shares, 12.2% of float, as of Oct 15, 2026.
What sector is NVCR in?
Healthcare, in the Surgical Instruments industry.

About NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

HQ: St. Helier, 1,605 employeesListed Oct 2, 2015novocure.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology